BO-112 Drug Asset Due Diligence Report 2026

This BO-112 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether BO-112 can convert its Oligonucleotide profile and MDA5 x RIG-I x TLR3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	BO-112 (query alias: BO-112)
Modality / target	Oligonucleotide; MDA5 x RIG-I x TLR3; MDA5 stimulants, RIG-I stimulants, TLR3 agonists
Highest global status	Phase 2
Originator	Highlight Therapeutics SL
Active developers	Highlight Therapeutics SL, Merck Sharp & Dohme LLC

The MCP disease footprint includes Basal Cell Carcinoma, Unresectable Melanoma, Stomach Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06422936	Phase 2	Active, not recruiting	60	Primary endpoint not disclosed in English source
NCT05265650	Phase 1/2	Unknown status	30	Primary endpoint not disclosed in English source
NCT04777708	Early Phase 1	Terminated	1	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase 2 Single Arm Clinical Study to Evaluate the Efficacy and Safety of Intratumoral Administration of BO-112 in Combination With Pembrolizumab in Subjects That Have Progressed on Anti-PD-1-based Therapy for Stage III or IV Melanoma

Phase 2; n=42; evaluation: Not stated in English source. Reported fields: ORR = 25.0 % (95%CI, 12.69 - 41.20)

BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

Phase 2; n=42; evaluation: Positive. Reported fields: ORR = 25 %

Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer

Phase 2; n=18; evaluation: Not stated in English source. Reported fields: Anti-tumour Efficacy:Overall Response Rate (ORR) Based on RECIST 1.1 = 0 Pts ; Anti-tumour Efficacy:Overall Response Rate (ORR) Based on RECIST 1.1 = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

BO-112 addresses Basal Cell Carcinoma, Unresectable Melanoma, Stomach Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Oligonucleotide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-12-10	Merck will assess the phase II combination of Bioncotech Therapeutics' BO-112 with Keytruda for the treatment of solid tumors with liver metastases.	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of antisense oligonucleotide in preparation of medicine for treating esophageal cancer”. The milestone feed surfaced a patent-application signal described as “Compositions for intratumoral administration and related methods”. The milestone feed surfaced a patent-application signal described as “Novel pharmaceutical composition comprising particles and methods of making same”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO